| Prev Close: | 65.25 |
|---|---|
| Open: | N/A |
| Bid: | 56.76 x 100 |
| Ask: | N/A |
| 1y Target Est: | 71.58 |
| Beta: | 1.07 |
| Next Earnings Date: | 22-Jul-13 |
| Day's Range: | N/A - N/A |
|---|---|
| 52wk Range: | 50.25 - 68.83 |
| Volume: | 0 |
| Avg Vol (3m): | 2,544,300 |
| Market Cap: | 30.70B |
| P/E (ttm): | 16.95 |
| EPS (ttm): | 3.85 |
| Div & Yield: | 1.04 (1.60%) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- InPlay: Covidien announces clinical trial data showing endoscopic ablation therapy eliminates precancerous esophageal tissue and significantly reduces disease progressionBriefing.com(Wed, May 22)
- Covidien Announces Clinical Trial Data Showing Endoscopic Ablation Therapy Eliminates Precancerous Esophageal Tissue and Significantly Reduces Disease ProgressionBusiness Wire(Wed, May 22)
- FDA Nod for COV's Advanced NellcorZacks(Tue, May 21)
- Covidien’s Technology Platform to Diagnose Early Lung Cancer Part of New Guidelines of American College of Chest PhysiciansBusiness Wire(Tue, May 21)
- Big Companies Borrowing Billionsat Motley Fool(Mon, May 20)
- 4 Healthcare Stock Stories Prescribed For Investorsat Wall St. Cheat Sheet(Mon, May 20)
- Covidien Receives FDA 510(k) Clearance for Nellcor™ Pulse Oximetry Motion ClaimsBusiness Wire(Mon, May 20)
- [video] Companies That Shine After Spinoffsat CNBC(Fri, May 17)
- Cramer: Break-Up Could Boost This Stock 19%at CNBC(Fri, May 17)
- Wall Street Transcript Interview with Mark W. Oelschlager, Portfolio Manager at Oak Associates, Ltd.: A Health Sciences Fund with a Long-Term FocusWall Street Transcript(Fri, May 17)
- COVIDIEN PLC Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Fri, May 17)
- Covidien PLC (COV): Today's Featured Health Services Laggardat TheStreet(Thu, May 16)
- COVIDIEN PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and EEDGAR Online(Thu, May 16)
- Covidien Prices Senior NotesZacks(Thu, May 16)
- 2 companies to expand operations in Puerto RicoAP(Wed, May 15)
Press Releases
- Covidien Announces Clinical Trial Data Showing Endoscopic Ablation Therapy Eliminates Precancerous Esophageal Tissue and Significantly Reduces Disease ProgressionBusiness Wire(Wed, May 22)
- Covidien’s Technology Platform to Diagnose Early Lung Cancer Part of New Guidelines of American College of Chest PhysiciansBusiness Wire(Tue, May 21)
- Covidien Receives FDA 510(k) Clearance for Nellcor™ Pulse Oximetry Motion ClaimsBusiness Wire(Mon, May 20)
Reports
- COV - Covidien Plc - Upgraded to a Buy - Company Analysis and ASR Ranking ReportAlpha Street Research(May 24)
- COV: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(May 22)
- Thomson Reuters Stock Report - COVIDIEN PLC (COV-N)Thomson Reuters Stock Report(May 22)